CompanyNGNENasdaqNew York, NY

Neurogene Inc.

Neurogene develops gene therapies for neurological diseases using proprietary EXACT transgene regulation technology.

SEC EDGAR ClinicalTrials.gov neurogene.com

SCHEDULE 13G/AAug 14Latest SEC filing

Aug 11Latest story

August 2026

Neurogene reports long-term Rett syndrome gene therapy data, extends cash into 2029

Aug 11Quarterly updateNeurogene Inc.

July 2026

Neurogene prices upsized stock offering, raises $134.8 million net

Jul 1PartnershipNeurogene Inc.

Neurogene prices $125 million public offering at $30.00 per share

Jul 1FinancingNeurogene Inc.

June 2026

Neurogene reports 30-month data for NGN-401 in Rett syndrome trial

Jun 29Clinical readoutNeurogene Inc.